

**BIOCON GROUP**

**FACT SHEET**

**September - 2015**

<b>BIOCON LIMITED (CONSOLIDATED)</b>		
<b>BALANCE SHEET</b>		(Rs. Crore)
	Sept 30, 2015	March 31, 2015
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholder's Funds</b>		
(a) Share capital	100	100
(b) Reserves and surplus	3,526	3,171
	<b>3,626</b>	<b>3,271</b>
<b>Minority interest</b>	308	172
<b>Non-current liabilities</b>		
(a) Long-term borrowings	878	770
(b) Deferred tax liability (net)	37	42
(c) Other long-term liabilities	555	552
(d) Long-term provisions	20	15
	<b>1,490</b>	<b>1,379</b>
<b>Current liabilities</b>		
(a) Short-term borrowings	316	261
(b) Trade payables	528	429
(c) Other current liabilities	590	706
(d) Short-term provisions	157	157
	<b>1,591</b>	<b>1,553</b>
<b>TOTAL</b>	<b>7,015</b>	<b>6,375</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Fixed assets	3,396	3,280
(b) Goodwill	26	26
(c) Long term loans and advances	392	369
(d) Other non-current assets	333	137
	<b>4,147</b>	<b>3,812</b>
<b>Current assets</b>		
(a) Current Investments	415	230
(b) Inventories	504	453
(c) Trade receivables	718	771
(d) Cash and cash equivalents	968	938
(e) Short term loans and advances	107	76
(f) Other current assets	156	96
	<b>2,868</b>	<b>2,564</b>
<b>TOTAL</b>	<b>7,015</b>	<b>6,376</b>

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crore)
Particulars	H1 FY 16	H1 FY 15	Variance
<b><u>INCOME</u></b>			
<b>Biopharmaceuticals</b>	<b>1,179</b>	<b>1,103</b>	<b>7%</b>
Biopharma *	948	877	8%
Branded formulations - India	231	226	2%
<b>Contract research</b>	<b>474</b>	<b>365</b>	<b>30%</b>
<b>Total Sales</b>	<b>1,653</b>	<b>1,468</b>	<b>13%</b>
Other income	65	47	41%
<b>TOTAL REVENUE</b>	<b>1,718</b>	<b>1,515</b>	<b>13%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	731	685	7%
Staff costs	278	242	15%
Research & Development **	107	66	62%
Other expenses	144	143	1%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,260</b>	<b>1,136</b>	
<b>EBITDA</b>	<b>458</b>	<b>379</b>	<b>21%</b>
Interest & Finance charges	7	6	30%
Depreciation & Amortisation	118	106	11%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>333</b>	<b>267</b>	<b>21%</b>
Exceptional item, Net	307	-	
<b>PBT</b>	<b>640</b>	<b>267</b>	<b>140%</b>
Taxes	71	53	
Taxes on exceptional item	104	-	
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>465</b>	<b>214</b>	<b>117%</b>
Minority interest	33	9	
<b>NET PROFIT FOR THE PERIOD</b>	<b>432</b>	<b>205</b>	<b>111%</b>
<b>EPS Rs.</b>	<b>21.6</b>	<b>10.3</b>	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>			
<i>* Biopharma Income includes:</i>			
<i>Licensing Income</i>	21	28	
<i>** Gross Research &amp; Development expenses</i>	183	144	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crore)
Particulars	Q2 FY 16	Q1 FY 16	Variance
<b><u>INCOME</u></b>			
<b>Biopharmaceuticals</b>	<b>578</b>	<b>601</b>	<b>-4%</b>
Biopharma *	459	489	-6%
Branded formulations - India	119	112	6%
<b>Contract research</b>	<b>250</b>	<b>224</b>	<b>12%</b>
<b>Total Sales</b>	<b>828</b>	<b>825</b>	<b>1%</b>
Other income	33	32	5%
<b>TOTAL REVENUE</b>	<b>861</b>	<b>857</b>	<b>1%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	368	363	2%
Staff costs	137	141	-3%
Research & Development **	57	50	15%
Other expenses	77	67	15%
<b>Manufacturing, staff &amp; other expenses</b>	<b>639</b>	<b>621</b>	
<b>EBITDA</b>	<b>222</b>	<b>236</b>	<b>-6%</b>
Interest & Finance charges	2	5	-34%
Depreciation & Amortisation	60	58	3%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>160</b>	<b>173</b>	<b>-8%</b>
Exceptional item, net	307	-	
<b>PBT</b>	<b>467</b>	<b>173</b>	<b>169%</b>
Taxes	34	37	
Taxes on exceptional item	104	-	
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>329</b>	<b>136</b>	<b>141%</b>
Minority interest	23	10	
<b>NET PROFIT FOR THE PERIOD</b>	<b>306</b>	<b>126</b>	<b>142%</b>
<b>EPS Rs.</b>	<b>15.3</b>	<b>6.3</b>	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	2	19	
** Gross Research & Development expenses	90	93	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crore)
Particulars	Q2 FY 16	Q2 FY 15	Variance
<b><u>INCOME</u></b>			
<b>Biopharmaceuticals</b>	<b>578</b>	<b>558</b>	<b>4%</b>
Biopharma *	459	442	4%
Branded formulations - India	119	116	3%
<b>Contract research</b>	<b>250</b>	<b>192</b>	<b>30%</b>
<b>Total Sales</b>	<b>828</b>	<b>750</b>	<b>11%</b>
Other income	33	23	45%
<b>TOTAL REVENUE</b>	<b>861</b>	<b>773</b>	<b>12%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	368	351	5%
Staff costs	137	125	9%
Research & Development **	57	35	64%
Other expenses	77	74	5%
<b>Manufacturing, staff &amp; other expenses</b>	<b>639</b>	<b>585</b>	
<b>EBITDA</b>	<b>222</b>	<b>188</b>	<b>18%</b>
Interest & Finance charges	2	5	-42%
Depreciation & Amortisation	60	54	10%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>160</b>	<b>129</b>	<b>24%</b>
Exceptional item, Net	307	-	
<b>PBT</b>	<b>467</b>	<b>129</b>	<b>263%</b>
Taxes	34	22	
Taxes on exceptional item	104	-	
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>329</b>	<b>107</b>	<b>208%</b>
Minority interest	23	5	
<b>NET PROFIT FOR THE PERIOD</b>	<b>306</b>	<b>102</b>	<b>200%</b>
<b>EPS Rs.</b>	<b>15.3</b>	<b>5.1</b>	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	2	9	
** Gross Research & Development expenses	90	81	